PMID: 8610646Apr 1, 1996Paper

A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study

American Journal of Clinical Oncology
J H MalfetanoR McGehee

Abstract

Didemnin B (NSC #335319) was administered i.v. to 26 evaluable patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix at 6.3 mg/m(2) every 28 days until progression of disease. No patient had had prior cytotoxic therapy alone. Some patients (4) were exposed to radiation sensitizers. There was one complete responder (4.5%). Six patients had stable disease (27.3%) and 15 (68.2%) had increasing disease. The toxicities were significant, with 11 patients (42.3%) experiencing grade 3 or 4 adverse effects. Didemnin B, when used with this dose and schedule, has minimal activity in squamous cell carcinoma of the cervix.

Citations

Oct 14, 2005·Current Oncology Reports·Krishnansu S Tewari, Bradley J Monk
Jan 6, 2001·Anti-cancer Drugs·B NuijenJ H Beijnen
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan Hilary Calvert
Feb 22, 2002·Medicinal Research Reviews·Matthew D Vera, Madeleine M Joullié
May 18, 2000·The Journal of Organic Chemistry·H VervoortR A Epifanio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.